Investigating the link between laryngopharyngeal reflux and idiopathic pulmonary fibrosis
The Role of Laryngopharyngeal Reflux in IPF
This study is testing if a new way to measure throat reflux can help doctors understand how it affects people with idiopathic pulmonary fibrosis.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 40 Years to 95 Years |
| Sex | All |
| Sponsor | National Jewish Health Academic / other |
| Locations | 1 site (Denver, Colorado) |
| Trial ID | NCT03418350 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the Supraglottic Index (SGI) as a reliable measure for identifying the presence and severity of laryngopharyngeal reflux (LPF) in patients with idiopathic pulmonary fibrosis (IPF). The researchers hypothesize that the SGI will show a stronger correlation with IPF severity compared to traditional gastroesophageal reflux (GER) data obtained from pH/impedance probes. Participants will be monitored over time to assess the relationship between SGI and IPF progression.
Who should consider this trial
Good fit: Ideal candidates include individuals aged 40-95 diagnosed with idiopathic pulmonary fibrosis who can communicate in English.
Not a fit: Patients who do not meet the inclusion criteria or are pregnant will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a new, easily collected index for assessing reflux in IPF patients, potentially leading to better management of their condition.
How similar studies have performed: While the approach of using SGI in this context is novel, similar studies have shown the importance of reflux assessment in respiratory conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of IPF * Age 40-95 * Able to read, speak, and understand English * If subjects are currently taking medication for reflux or GERD, they much be on a stable does for at least 4 weeks prior to consent. Exclusion Criteria: * Patients who do not meet all inclusion criteria * Pregnant females
Where this trial is running
Denver, Colorado
- National Jewish Health — Denver, Colorado, United States (Recruiting)
Study contacts
- Principal investigator: Matthew Koslow, DO — National Jewish Health
- Study coordinator: Matthew Koslow, MPH
- Email: ILDresearch@njhealth.org
- Phone: 303-398-1996
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.